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During the expansion of fat mass in obesity, vascularization of
adipose tissue is insufﬁcient to maintain tissue normoxia. Local
hypoxia develops and may result in altered adipokine expression,
proinﬂammatory macrophage recruitment, and insulin resistance.
We investigated whether an increase in adipose tissue angiogen-
esis could protect against obesity-induced hypoxia and, conse-
quently, insulin resistance. Transgenic mice overexpressing
vascular endothelial growth factor (VEGF) in brown adipose
tissue (BAT) and white adipose tissue (WAT) were generated.
Vessel formation, metabolism, and inﬂammation were studied in
VEGF transgenic mice and wild-type littermates fed chow or
a high-fat diet. Overexpression of VEGF resulted in increased
blood vessel number and size in both WAT and BAT and
protection against high-fat diet–induced hypoxia and obesity,
with no differences in food intake. This was associated with in-
creased thermogenesis and energy expenditure. Moreover, whole-
body insulin sensitivity and glucose tolerance were improved.
Transgenic mice presented increased macrophage inﬁltration, with
a higher number of M2 anti-inﬂammatory and fewer M1 proinﬂam-
matory macrophages than wild-type littermates, thus maintaining
an anti-inﬂammatory milieu that could avoid insulin resistance.
These studies suggest that overexpression of VEGF in adipose
tissue is a potential therapeutic strategy for the prevention of obe-
sity and insulin resistance. Diabetes 61:1801–1813, 2012
Obesity, an epidemic disease whose prevalenceis increasing at an alarming rate, is a major riskfactor for serious chronic diseases, includinginsulin resistance, type 2 diabetes, and cardio-
vascular disease (1,2). However, the mechanisms through
which obesity leads to these metabolic complications are
not fully understood. Adipose tissue mass increases during
obesity, and to provide sufﬁcient oxygen and nutrients to all
cells, angiogenesis has to support adipose tissue growth (3).
Several studies postulate that during obesity, this enlarge-
ment of the vascular network is not sufﬁcient to supply
enough oxygen to all adipocytes and local hypoxia occurs
(4–7). It has been hypothesized that this insufﬁcient adipose
tissue blood ﬂow may trigger insulin resistance via effects
on inﬂammation, adipokine expression, and/or adipocyte
differentiation (8–10).
Adipose tissue macrophages (ATMs) play an important
role in the establishment of the chronic inﬂammatory state
associated with obesity and its metabolic dysfunctions
(11,12). Lumeng et al. (13) demonstrated in recent studies
that ATMs from lean mice are M2 or “alternatively acti-
vated” macrophages, whereas ATMs from obese mice are
predominantly M1 or “classically activated” macrophages.
Whereas M2 macrophages present anti-inﬂammatory prop-
erties and are associated with angiogenesis and wound re-
pair, M1 macrophages are associated with inﬂammation.
The cross-talk among proinﬂammatory macrophages, adi-
pocytes, and endothelial cells during obesity may aggravate
the inﬂammatory state, resulting in increased secretion of
proinﬂammatory molecules, including acute-phase reactants,
procoagulant factors, cytokines, and chemokines (8,14,15).
These factors can cause local and/or systemic insulin re-
sistance in a paracrine, autocrine, and/or endocrine fashion.
We therefore hypothesized that an increase in adipose
tissue angiogenesis may protect from obesity-induced
hypoxia, and consequently, from inﬂammation and insulin
resistance in this tissue. Vascular endothelial growth factor
(VEGF) is a key factor involved in adipose tissue angio-
genesis (16–18); however, its role and expression levels
during obesity remain unclear (6,7,19). Thus, to determine
the effects of an increase in VEGF levels in adipose tissue,
transgenic mice overexpressing VEGF in WAT and BAT
were obtained. Our results indicate that VEGF over-
expression led to increases in vascularization and in the
amount of M2 anti-inﬂammatory macrophages, which pro-
tected transgenic mice not only against high-fat diet (HFD)–
induced obesity but also insulin resistance.
RESEARCH DESIGN AND METHODS
Animals. Transgenic mice expressing the aP2/Vegf chimeric gene were
obtained by microinjection of oocytes from C57Bl6/SJL mice. Mice were kept
in a pathogen-free facility (Servei d’Estabulació de Ratolins-Centre de Bio-
tecnologia Animal i Teràpia Gènica) and maintained under a 12-h light–dark
cycle at 22°C. Mice were fed ad libitum for 15 weeks with a chow diet (2018S
Harlan Teklad, Madison, WI) or an HFD (TD88137 Harlan Teklad). When stated,
mice were fasted for 16 h.
An indirect open circuit calorimeter (Oxylet, Panlab, Cornellà, Spain) was
used to monitor oxygen consumption, carbon dioxide production, and loco-
motor activity in eight metabolic chambers simultaneously. Mice were in-
dividualized and acclimated to the metabolic chambers for 24 h, and data were
collected every 15 min for 3 min in each cage. Data were taken from the light
and dark cycle. The LE5007 system (Panlab) was used to measure blood
pressure, and animals were kept in a restrainer and heated using the Heater
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Scanner LE 5650/6 (Panlab). Animals were anesthetized and killed, and tissues
of interest were excised and kept at 280°C or preserved with formalin until
analysis. Animal care and experimental procedures were approved by the
Ethics Committee in Animal and Human Experimentation of the Universitat
Autònoma de Barcelona.
Gene expression analysis. For quantitative real-time PCR analysis, total RNA
was extracted from different tissues using TriPure isolation reagent (Roche,
Mannheim, Germany) for nonfat tissues and QIAZOL (Qiagen, Hilden, Germany)
for fat tissues, and Rneasy Mini Kit (Qiagen). Total RNA (1mg) was retro-
transcribed using the SuperScript VILO cDNA Synthesis Kit (Invitrogen,
Carlsbad, CA). Real-time PCR was performed in a SmartCycler II (Cepheid,
Sunnyvale, CA) using EXPRESS 23 qPCR SuperMix (Invitrogen). Oligonu-
cleotide sequences were: Vegfa164–FW: 59-AGACAGAACAAAGCCAGAAATC-
AC-39, RV: 59-CACGTCTGCGGATCTTGGAC-39; Pecam-1–FW: 59-CTGGTG-
CTCTATGCAAGCCTC-39, RV: 59-CGGTGCTGAGACCTGCTTT-39; Kdr–FW:
59-AGCTTGGCTCACAGGCAACAT-39, RV: 59-TGGCCCGCTTAACGGTCCG-
TA-39; Srebf1–FW: 59-GGAGCCATGGATTGCACATT-39, RV: 59-GCTTCCAGA-
GAGGAGGCCAG-39; Fasn–FW: 59-GCTGCGGAAACTTCAGGAAAT-39, RV:
59-AGAGACGTGTCACTCCTGGAC-39; Il10–FW: 59-CTATGCTGCCTGCTCT-
TACTG-39, RV: 59-AACCCAAGTAACCCTTAAAGTC-39; Arg1–FW: 59-GGAATC-
TGCATGGGCAACCTGTGT-39, RV: 59-AGGGTCTACGTCTCGCAAGCCA-39;
Hif1a–FW: 59-GACTAGACAAAGTTCACCTGAGA-39, RV: 59-CGCTATCCA-
CATCAAAGCAA-39; Cxcl12–FW: 59-TGCATCAGTGACGGTAAACCA-39, RV:
59-TTCTTCAGCCGTGCAACAATC-39; Lep–FW: 59-GAGACCCCTGTGTCGGT-
TC-39, RV: 59-CTGCGTGTGTGAAATGTCATTG-39; Adipoq–FW: 59-TGTTCCT-
CTTAATCCTGCCCA-39, RV: 59-CCAACCTGCACAAGTTCCCTT-39; and 36B4–
FW: 59-TCCCACCTTGTCTCCAGTCT-39, RV: 59-ACTGGTCTAGGACCCGA-
GAAG-39.
Western blot analysis. Tissues were homogenized in protein lysis buffer as
previously described (20). Primary antibodies were anti-VEGF (Abcam ab46154,
Cambridge, U.K.); anti–hypoxia-inducible factor (HIF)-1a (Abcam ab1); anti-
uncoupling protein (UCP)1 (Abcam ab10983); anti-peroxisome proliferator–
activated receptor g coactivator (PGC)-1a (Chemicon AB3242, Millipore,
Billerica, MA); anti-Akt (Cell Signaling 9272, Danvers, MA) and anti–phospho-Akt
(Ser473) (Cell Signaling 9271).
Immunohistochemical and morphometric analysis. Tissues were ﬁxed for
24 h in formalin, embedded in parafﬁn, and sectioned. For immunohisto-
chemical detection, sections were deparafﬁnized and incubated overnight at 4°C
with antibody against Mac-2 (Cederlane CL8942AP, Ontario, Canada) or against
VEGF (Abcam ab46154), washed with PBS three times for 5 min for each wash,
incubated with the corresponding secondary antibodies, and revealed with
ABC Complex (Vector Laboratories Ltd., Peterborough, U.K.). Sections were
counterstained in Mayer’s hematoxylin.
Measurement of the adipocyte area. A morphometric study of adipocytes
size was performed inWAT sections stained with hematoxylin-eosin. Adipocytes
area was determined as previously described (21). Four animals per group were
used and at least 250 adipocytes per animal were analyzed.
Transmission electron microscopy analysis. WAT and BAT samples were
processed as described elsewhere (22).
Fluorescein angiography. Mice were injected with 10 mL/kg ﬂuorescein
isothiocyanate–conjugated dextran solution (50 mg/mL; Sigma-Aldrich, St. Louis,
MO). After 10 min, animals were killed and tissues were dissected and placed in
formalin. Samples were incubated with rhodamine-phalloidin, placed on glass
slides covered with mounting media for ﬂuorescence (Vectashield, Peterborough,
U.K.), and analyzed on a laser-scanning confocal microscope (Leica Mycrosys-
tems, Wetzlar, Germany) at original magniﬁcation 3400. Each image represents
an overlay of 20 images (WAT) or 30 images (BAT) separated by 1 mm. For
morphometric analysis, the vessel area of 10 consecutive images was measured.
Hypoxyprobe staining. Hypoxyprobe staining was performed using the
Hypoxyprobe-1 Kit (Hypoxyprobe Inc., Burlington,MA). Pimonidazole (60mg/kg)
was injected into mice via a tail vein 30 min before sampling. Samples were
removed, ﬁxed, and processed according to the manufacturer’s instructions.
Glucose and insulin-tolerance tests. Glucose and insulin-tolerance tests
were performed as previously described (20). Brieﬂy, mice were given an in-
traperitoneal injection of glucose or insulin, and the glucose concentration
was determined in blood samples at indicated time points.
Insulin signaling. To study insulin signaling, overnight fasted animals were
anesthetized and quadriceps and a piece of epididymal adipose tissue were
excised and frozen into liquid nitrogen. Immediately, mice were intraperitoneally
injected with insulin (0.15 units/g body weight). Ten minutes later, other tissues
were excised and frozen. Protein extracts of different samples were obtained for
Western blot analysis.
Enzyme, metabolite, and hormone assays. Tissue triglyceride content was
determined by extracting total lipids from liver, quadriceps, kidney, and heart
samples with chloroform-methanol (2:1 vol/vol), as described by Carr et al. (23).
Triglycerides, total cholesterol, and HDL cholesterol were quantiﬁed spec-
trophotometrically using an enzymatic assay kit (Horiba-ABX, Montpellier,
France). Serum free fatty acids (FFAs) were measured by the acyl-CoA
synthase and acyl-CoA oxidase methods (Wako Chemicals GmbH, Neuss,
Germany). Serum glycerol concentration was determined enzymatically (Randox
Laboratory, Crumlin, U.K.). All biochemical parameters were determined using
a Pentra 400 Analyzer (Horiba-ABX). Glucose was determined using a Gluc-
ometer Elite analyzer (Bayer, Leverkusen, Germany), and insulin levels were
measured using the Rat Insulin ELISA Kit (Crystal Chemical, Chicago, IL). Leptin
concentration was determined using the Mouse Leptin ELISA Kit (Crystal
Chemical). VEGF protein levels were measured using the Mouse VEGF ELISA
Kit (Calbiochem, Darmstadt, Germany). Serum monocyte chemoattractant pro-
tein (MCP)-1 levels were determined using the Mouse MCP-1 ELISA Kit (eBio-
science, San Diego, CA), and serum adiponectin levels were measured by mouse/
rat RIA Kit (Millipore, Billerica, MA). MCP-1, interferon (IFN)-g, interleukin (IL)-6,
and tumor necrosis factor (TNF)-a WAT protein levels were measured by
Luminex xMAP using Millipore reagents and instructions.
Isolation of the WAT stroma vascular fraction. WAT was excised and put
in a tube containing PBS/BSA 0.5% solution (2 mL) at 37°C. The tissue was
minced and digested at 37°C for 30 min by the addition of 1 mg/mL collagenase
P from Clostridium histolyticum (Roche). The supernatant was ﬁltered
through a 30-mm pore ﬁlter (Partec CellTrics, Görlitz, Deutschland) to obtain
a single cell suspension, and the ﬁltrate was recollected in Falcon tubes. After
the addition of PBS/BSA 0.5%, the ﬁltrate was spun. Supernatant was elimi-
nated, and the pellet was resuspended in RBC lysis buffer (eBioscience) and
incubated for 5 min to break the erythrocytes. After addition of PBS/BSA 0.5%
and a spin, the pellet was resuspended in 500 mL PBS/BSA 0.5%.
Flow cytometry. The stroma vascular fraction was incubated with speciﬁc
antibodies: phycoerythrin (PE) anti-mouse cluster of differentiation (CD)11b
(BD Pharmigen 557397, Franklin Lakes, NJ), PE/Cy7 anti-mouse CD11b
(Biolegend 101216, San Diego, CA), PE anti-mouse CD11c (BD Pharmigen
557401), ﬂuorescein isothiocyanate anti-mouse F4/80 (Biolegend 123107),
AlexaFluor 488 anti-mouse CD301 (AdB Serotec MCA2391A488T, Düsseldorf,
Germany), and PE/Cy5 anti-mouse major histocompatibility complex (MHC) II
(Biolegend 107611). Flow cytometric analysis was performed on a FC500 MPL
(Beckman Coulter) equipped with an argon ion laser (488 nm, 20-mW output)
and a red helium-neon laser (633 nm, 20-mW output). Data were analyzed
using FCS3 Express software (De Novo Software, Los Angeles, CA).
Isolation and culture of bone marrow–derived macrophages (BMDMs).
BMDMs were prepared from the femur and tibia of mice. Cells were cultured
with complete RPMI supplemented with macrophage colony-stimulating factor
(Gibco, Invitrogen) for 7 days (24) and then treated with 100 ng/mL recombi-
nant mVEGF (Cell Signaling) for 24 h before collection of the cells.
Statistical analysis. All values are expressed as the mean6 SEM. Differences
between groups were compared by Student t test. Statistical signiﬁcance was
considered if P , 0.05.
RESULTS
Adipose-speciﬁc overexpression of VEGF leads to
increased vessel density. Two transgenic mouse lines
(L1 and L2) expressing VEGF under the control of the
adipose-speciﬁc aP2 promoter were obtained. L1 showed
a slight increase in VEGF expression levels (data not
shown), whereas L2 showed a high increase and this line
was further studied. After Northern blot analysis, a marked
increase in total Vegf mRNA levels was detected in WAT
and BAT but not in skeletal muscle or liver from transgenic
animals (Fig. 1A). Moreover, Vegf164 mRNA levels were
highly increased in different WAT depots (epididymal,
retroperitoneal, and subcutaneous) and in interscapular
BAT of transgenic mice (Fig. 1B). This increase was par-
allel to an increase in VEGF protein levels detected by
immunohistochemistry or by Western blot (Fig. 1C and D).
However, no differences in VEGF serum levels were
detected between groups, probably due to the retention of
VEGF by the extracellular matrix (Fig. 1E).
Because VEGF is a potent activator of angiogenesis, the
effects of VEGF overexpression on vascularization were
analyzed. Macroscopic observation showed that WAT and
BAT were reddish (Fig. 1F), suggesting increased blood
ﬂow in the adipose tissue of transgenic mice. After tail-vein
dextran-conjugated ﬂuorescein injection and phalloidin
staining, WAT and BAT angiographies showed an increase
in functional blood vessels in the transgenic mice (Fig. 1G).
VEGF OVEREXPRESSION IN ADIPOSE TISSUE
1802 DIABETES, VOL. 61, JULY 2012 diabetes.diabetesjournals.org
The vessel/adipocyte area in wild-type compared with trans-
genic mice related to adipocyte area was increased in epi-
didymal (0.27 6 0.08 and 1.16 6 0.17%, n = 4; P # 0.01),
retroperitoneal (0.24 6 0.06 and 0.59 6 0.10%, n = 4; P #
0.05), and subcutaneous (0.236 0.05 and 0.476 0.05%, n = 4;
P # 0.05) fat depots. Moreover, the speciﬁcity of the in-
crease in vessel density in epididymal, retroperitoneal,
subcutaneous WAT and interscapular BAT was corrobo-
rated by Pecam-1 and Kdr expression levels (Supple-
mentary Fig. 1A and B).
Transmission electron microscopy showed that capillaries
from transgenic WAT and BAT were highly dilated (Fig. 1H),
suggesting increased blood ﬂow and oxygen supply to sur-
rounding cells. Some edema was observed, suggesting an ef-
fect of VEGF on vessel permeability, although no fenestrations
and a similar number of vesicles were observed in BAT
capillaries of transgenic mice (Supplementary Fig. 1C and D).
Metabolic parameters were determined in 6- and 12-month-old
mice, and no differences between wild-type and transgenic
mice were observed (Supplementary Table 1).
FIG. 1. Adipose-speciﬁc overexpression of VEGF led to increased vessel density. A: Representative Northern blot of epididymal WAT, BAT, skeletal
muscle, and liver from wild-type (Wt) and transgenic (Tg) mice speciﬁc for Vegfa. B: Vegfa164 expression was analyzed by quantitative real-time PCR
in epididymal WAT (eWAT), retroperitoneal WAT (rWAT), subcutaneous WAT (scWAT), and BAT and was normalized by 36B4 expression. Data
represent the mean6 SEM of at least seven animals per group. $P < 0.05 vs. Wt. $$P < 0.01 vs. Wt. C: VEGF immunohistochemistry in WAT and BAT.
Figure shows representative images at original magniﬁcation3200, with insets at higher magniﬁcation.D: Representative WAT and BATWestern blots
blotted with an antibody against VEGF and showing a band of 45 KDa corresponding to VEGF. E: Serum VEGF levels were measured in serum samples
by enzyme-linked immunosorbent assay. Data represent the mean6 SEM of at least seven animals per group. F: Representative macroscopic images of
eWAT (left) and interscapular BAT (right). G: Images of WAT and BAT angiographies were taken after a tail-vein dextran-conjugated ﬂuorescein
injection (green) and in toto with phalloidin (red), by confocal microscopy (original magniﬁcation 3400). Angiographies represent an overlay of 20
images (WAT) or 30 images (BAT) separated by 1 mm.H: Transmission electronmicroscopy study of capillary ultrastructure inWAT and BAT (original
magniﬁcation32,000). L, lipid droplets; V, blood vessels; *, edema. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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Lower adiposity in aP2VEGF transgenic mice fed an
HFD. To examine whether an increase in adipose tissue
angiogenesis could protect against obesity-induced hyp-
oxia and, consequently, avoid inﬂammation and insulin
resistance, transgenic mice were studied under HFD con-
ditions. After 15 weeks of the HFD, weight gain increased
by 30% in wild-type mice but only by 10% in aP2VEGF
transgenic mice (Fig. 2A), although food intake was similar
between the groups (Fig. 2B). In parallel to weight gain,
the WAT weight and the adipocyte mean size increases
were greater in wild-type mice than in transgenic mice
(Fig. 2C and D). The frequency distribution of the area of
white adipocytes was also different between groups. Wild-
type mice fed an HFD presented fewer small adipocytes and
an increase in the number of large adipocytes (Fig. 2E). In
contrast, transgenic mice fed an HFD only presented an in-
creased number of intermediate-sized adipocytes (Fig. 2E).
Therefore, the HFD-induced hypertrophy of adipocytes ob-
served in wild-type mice was attenuated in transgenic mice
overexpressing VEGF. In addition, local hypoxia in WAT
was only detected in control mice fed an HFD, suggesting
that transgenic mice did not develop hypoxia (Fig. 2F).
Accordingly, the HFD increased mRNA and protein lev-
els of the hypoxia-inducible transcription factor (Hif1a)
in wild-type mice but not in transgenic mice (Fig. 2G
and H). Thus, VEGF overexpression in adipose tissue
protected transgenic mice from diet-induced obesity and
local hypoxia.
Transgenic mice showed increased thermogenesis
activity. Histologic analysis of BAT in mice fed the chow
diet showed that the morphology of this tissue was altered
in transgenic mice, probably due to the presence of high
vascularization (Fig. 3A). In addition, the interscapular BAT
weight was almost twofold higher in transgenic mice than in
wild-type animals (Fig. 3B). In contrast, when fed an HFD,
BAT weight increased only in wild-type animals (Fig. 3B),
probably due to less lipid deposition in transgenic mice.
Total UCP1 (Fig. 3C) and PGC-1a (Fig. 3D) protein levels
increased signiﬁcantly in BAT of transgenic mice fed an
HFD compared with wild-type mice. Accordingly, the en-
ergy expenditure of HFD-fed transgenic mice during the
dark cycle (activity phase) was higher than that of wild-type
mice (Fig. 3E), without changes in spontaneous locomotor
activity (Fig. 3F). Body temperature was also more elevated
in transgenic mice fed a chow diet compared with wild-type
mice (Fig. 3G). However, body temperature increased to the
same extent in wild-type and transgenic mice fed an HFD
(Fig. 3G). Altogether, these data suggest that transgenic
mice have increased thermogenic activity.
Less fat accumulation in nonadipose tissues of transgenic
mice. Liver histologic sections showed no morphologic
alterations in transgenic mice fed a chow diet. When fed an
HFD, wild-type mice showed increased lipid accumulation in
hepatocytes compared with transgenic mice (Fig. 4A and B).
Similarly, sterol regulatory element-binding protein-1c
(Srebf1) and fatty acid synthase (Fasn) expression were
both increased in wild-type animals fed an HFD but not in
transgenic mice fed an HFD (Fig. 4C and D). No differ-
ences in triglyceride content in skeletal muscle, heart,
and kidney were detected between groups fed a chow
diet. On an HFD, triglyceride content in skeletal muscle
increased to a greater extent in wild-type animals than in
transgenic mice but remained unchanged in heart and kid-
ney (Fig. 4E–G).
Lipid proﬁle after an HFD.Wild-type animals fed an HFD
presented increased serum FFA and glycerol, whereas
transgenic mice had a similar increase in FFA but not in
glycerol levels (Fig. 5A and B). This suggested differences in
FFA re-esteriﬁcation between wild-type and transgenic
mice. Similarly, transgenic mice fed an HFD presented lower
triglyceride levels than wild-type mice (Fig. 5C). Transgenic
mice also showed a lower HFD-induced increase in total and
HDL cholesterol levels than wild-type mice (Fig. 5D and E).
The origin of these alterations is not known. No changes in
blood pressure were observed in transgenic mice (Fig. 5F).
aP2VEGF transgenic mice are protected against diet-
induced glucose intolerance and insulin resistance.
Wild-type and transgenic animals fed a chow diet were
normoglycemic, normoinsulinemic, and presented similar
insulin sensitivity and glucose tolerance (Fig. 6). However,
glucose and insulin levels signiﬁcantly increased in wild-
type mice fed an HFD but remained lower in transgenic
mice (Fig. 6A and B). An intraperitoneal insulin-tolerance
test showed that insulin response was blunted in HFD-fed
wild-type mice, whereas glucose levels were reduced by 40%
in transgenic mice, indicating that they remained insulin-
sensitive (Fig. 6C). In addition, wild-type mice fed an HFD
presented impaired glucose tolerance whereas transgenic
mice showed preserved glucose response (Fig. 6D). Accord-
ingly, in adipose tissue and skeletal muscle, insulin-stimulated
phosphorylation of Akt on Ser473 remained unaltered by
the HFD in transgenic mice, whereas the insulin response
was blunted in wild-type mice (Fig. 6E). Therefore, these
results indicated that transgenic mice fed an HFD remained
glucose-tolerant and insulin-sensitive.
VEGF overexpression increases M2 anti-inﬂammatory
macrophages and reduces M1 proinﬂammatory
macrophages in adipose tissue. In addition to inducing
angiogenesis, VEGF is involved in macrophage recruitment
(25). In wild-type mice, cells positive for the macrophage
marker MAC-2 were only detected in BAT and WAT under
HFD conditions (Fig. 7A). In contrast, transgenic mice fed an
HFD or chow presented MAC-2–positive cells in both WAT
and BAT (Fig. 7A). The population of the inﬁltrate was fur-
ther analyzed by ﬂow cytometry analysis. Accordingly, the
percentage of CD11b+F480+ cells was lower in wild-type
mice fed chow than in all the other groups (Fig. 7B). The
percentage of MHCII+CD11b+ and MHCII+CD11c+ double-
positive cells was increased in HFD-fed wild-type mice but
not in transgenic mice (Fig. 7C and D), indicating that the
HFD induced a higher capacity for antigen presentation in
macrophages and dendritic cells of wild-type mice. More-
over, transgenic mice fed both chow and the HFD pre-
sented lower M1 proinﬂammatory macrophages (decreased
CD11chigh F4/80+ cells; Fig. 7E) and an increase in M2 anti-
inﬂammatory macrophages (increased MGL1+CD11b+ cells;
Fig. 7F).
The enrichment of M2 vs M1 macrophages in the WAT of
transgenic mice could inﬂuence the proﬁle of proin-
ﬂammatory cytokines production. Indeed, levels of leptin
and MCP-1 were dramatically increased in wild-type mice
fed an HFD but were only slightly increased in transgenic
mice (Fig. 8A–D). Similarly, the WAT of wild-type but not
transgenic mice presented increased IFN-g protein levels
under the HFD (Fig. 8E). In addition, transgenic mice had
lower IL-6 and TNF-a WAT protein levels (Fig. 8F and G).
In contrast, levels of the anti-inﬂammatory adipokine,
adiponectin, remained unchanged in all groups (Fig. 8H
and I).
To examine whether VEGF could switch macrophages
to the M2 phenotype, BMDMs were treated with VEGF;
however, this treatment did not lead to an increase in M2
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FIG. 2. Reduced adiposity in aP2VEGF transgenic (Tg) mice fed an HFD. Weight gain (A) and food intake (B), calculated as estimated metabo-
lisable energy of wild-type (Wt) and Tg mice fed chow or an HFD for 15 weeks. Data represent the mean 6 SEM of at least 10 animals per group.
C: Epididymal WAT weight. D: Mean adipocyte area. E: Frequency distribution of adipocyte area in Wt and Tg mice fed chow or an HFD. Data
represent the mean 6 SEM of at least four animals per group. F: Representative hypoxyprobe sections of epididymal WAT, counterstained with
hematoxylin (original magniﬁcation 3400). Red arrows indicate hypoxyprobe signal. G: Hif1a expression was analyzed by quantitative real-time
PCR in epididymal WAT (eWAT), retroperitoneal WAT (rWAT), and subcutaneous WAT (scWAT), and was normalized by 36B4 expression. Data
represent the mean6 SEM of at least seven animals per group.H: Representative WAT Western blot blotted with an antibody against HIF-1a. *P<
0.05 vs. Wt HFD. **P < 0.01 vs. Wt HFD. $P < 0.05 vs. Wt chow. $$P < 0.01 vs. Wt chow. ^^P < 0.01 vs. Tg chow. (A high-quality digital repre-
sentation of this ﬁgure is available in the online issue.)
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markers such as Arg1 or Il10 (Fig. 8J and K). Because
VEGF receptor 2 (VEGFR2) (Kdr) together with the che-
mokine stromal cell-derived factor (SDF)-1 (Cxcl12) are
involved in VEGF-induced macrophage mobilization and
retention in adipose tissue (26), expression of Kdr in
macrophages and Cxcl12 in adipose tissue was examined.
In transgenic mice, Kdr and Cxcl12 expression were both
increased compared with wild-type mice (Fig. 8L and M).
FIG. 3. Transgenic (Tg) mice showed increased BAT thermogenesis and energy expenditure. A: Representative sections of BAT, stained with
hematoxylin-eosin (original magniﬁcation3200) for Tg and wild-type (Wt) mice.B: Interscapular BAT tissue weight. Data represent the mean6 SEM
of at least 10 animals per group. Total content of UCP1 (C) and PGC-1a (D) were determined by Western blot densitometry, taking into account the
amount of total BAT protein. Data represent the mean6 SEM of at least four animals per group. Energy expenditure (E) and locomotor activity (F)
was measured with an indirect open circuit calorimeter in Wt and Tg mice fed chow or an HFD for 15 weeks. Data were taken during the light and dark
cycles and represent the mean6 SEM of at least eight animals per group. G: Body temperature was measured in awake animals using an intrarectal
probe. Data represent the mean 6 SEM of at least 10 animals per group. *P < 0.05 vs. Wt HFD. $P < 0.05 vs. Wt chow. $$P < 0.01 vs. Wt chow.
^P < 0.05 vs. Tg chow. ^^P < 0.01 vs. Tg chow. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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FIG. 4. Transgenic (Tg) mice showed decreased hepatic fat accumulation compared with wild-type (Wt) mice. A: Representative sections of liver,
stained with hematoxylin-eosin (original magniﬁcation 3400). B: Liver triglyceride content was determined as indicated in RESEARCH DESIGN AND
METHODS. Srebf1 (C) and Fasn (D) liver expression were analyzed by quantitative real-time PCR and normalized by 36B4 expression. Triglyceride
content was determined in muscle (E), kidney (F), and heart (G) as indicated in RESEARCH DESIGN AND METHODS. Data represent the mean6 SEM of at
least 10 animals per group. *P < 0.05 vs. Wt HFD. $P < 0.05 vs. Wt chow. $$P < 0.01 vs. Wt chow. ^^P < 0.01 vs. Tg chow. (A high-quality digital
representation of this ﬁgure is available in the online issue.)
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These results suggest that VEGF may attract M2 macro-
phages in adipose tissue through macrophage-VEGFR2
and SDF1.
DISCUSSION
Studies have reported that angiogenesis fails to maintain
normoxia in adipose depots and that local hypoxia occurs
in obesity (4,5). Thus, it has been hypothesized that this
reduction in adipose tissue blood ﬂow may trigger insulin
resistance. To examine whether an increase in adipose
tissue angiogenesis could protect against insulin resis-
tance, transgenic mice overexpressing VEGF in adipose
tissue were generated. Although adipose tissue angiogen-
esis can be promoted by several factors, such as leptin,
HIF-1a, or VEGF, overexpression of leptin in adipose tis-
sue failed to induce angiogenesis (27), and transgenic mice
with dominant, active HIF-1a presented ﬁbrosis but not
vessel growth (28). Our study showed that overexpression
of VEGF164 was able to induce vessel formation in both
WAT and BAT. Moreover, ﬂuorescein angiographies and
electron microscopy studies both showed that these blood
vessels were functional and more dilated. In accordance
with our results, other studies in which VEGF164 was
expressed demonstrated the ability of this isoform to induce
the development of new vessels (29). Furthermore, we did
not observe an increase in vessel density in nonadipose
tissues of the transgenic mice. Indeed, to enhance angio-
genesis, the correct relationship between VEGF gradient
and concentration is determinant (30), and in our transgenic
mice, this may only be present in the site of production.
To our knowledge, this is the ﬁrst time that the effects of
increased angiogenesis on adipose tissue growth and in-
sulin resistance have been studied. However, because it
is well established that the expansion of adipose tissue
is supported by angiogenesis (31), several studies have
developed antiangiogenesis approaches to achieve a ther-
apeutic intervention of obesity. Administration of angio-
genic inhibitors to obese mice has resulted in decreased
adipose tissue mass and concomitant weight loss (17,32,33).
Although the inhibition of angiogenesis seems to prevent
the expansion of adipose tissue mass, our results demon-
strate that an increase in vessel density does not result in an
increase in the mass of WAT.
FIG. 5. Levels of circulating metabolites and blood pressure were determined in transgenic (Tg) and wild-type (Wt) mice fed chow and HFD. Serum
levels of FFAs (A), glycerol (B), triglycerides (C), total cholesterol (D), and HDL cholesterol (E) were analyzed, and systolic and diastolic blood
pressure (F) was determined as indicated in RESEARCH DESIGN AND METHODS. Data represent the mean 6 SEM of at least 10 animals per group. *P <
0.05 vs. Wt HFD. **P < 0.01 vs. Wt HFD. $$P < 0.01 vs. Wt chow. ^^P < 0.01 vs. Tg chow.
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Noticeably, the protection against HFD-induced obesity
of transgenic mice could be explained by the enhanced
energy expenditure and the increase in total protein levels
of key genes involved in thermogenesis and mitochondrial
biogenesis in BAT, such as UCP1 and PGC-1a (34). In ac-
cordance with our studies, transgenic mice overexpressing
UCP1 in adipose tissue are protected against HFD-induced
obesity (35). Moreover, the greater BAT vessel density of
transgenic mice may be comparable to that observed during
cold exposure. Indeed, cold exposure enhances BAT an-
giogenesis in a hypoxia-independent but VEGF-dependent
process (36), and increased BAT vessel density enables
higher rate of blood perfusion to supply oxygen and FFAs
and to facilitate heat dissipation, all of them necessary for
UCP1-induced thermogenesis. Taken together, our data
suggest that increased vascularization in the BAT of trans-
genic mice increases BAT size and enhances UCP1 ex-
pression and thermogenesis. Thus, phenotypic changes in
the body weight of aP2VEGF transgenic mice may be at-
tributed to the increased energy expenditure and thermo-
genic activity of BAT. Furthermore, recent studies suggest
that BAT is more abundant in adult humans than previously
recognized (37–40). As a consequence, strategies aimed at
stimulating the generation and/or activation of BAT, such as
enhancing BAT angiogenesis, might lead to new approaches
to counteract obesity.
Transgenic mice were protected not only against HFD-
induced obesity but also systemic insulin resistance. Glu-
cose tolerance and insulin sensitivity were both improved
in transgenic mice. The absence of insulin resistance in
these mice may be linked not only to a lack of fat accu-
mulation but also to decreased inﬁltration of proinﬂamma-
tory macrophages. It is well accepted that adipose tissue
contains BMDMs and that the content of these macro-
phages correlates with the degree of obesity and insulin
resistance (12,41). Strikingly, despite being neither obese
nor insulin resistant, transgenic mice presented signiﬁcant
macrophage inﬁltration when fed not only an HFD but also
the chow diet. However, ﬂow cytometry analysis indicated
lower M1 proinﬂammatory and increasedM2 anti-inﬂammatory
macrophages in the adipose tissue of aP2VEGF transgenic
mice.
Our current understanding of how adipose tissue mac-
rophages promote obesity-associated insulin resistance is
based on the model proposed by Lumeng et al. (13), in
which the recruitment of M1 macrophages promotes the
FIG. 6. aP2VEGF transgenic (Tg) mice are protected against diet-induced glucose intolerance and insulin resistance compared with wild-type (Wt)
mice. Blood glucose (A) and insulin (B) levels are shown in chow and HFD-fed mice. Data represent the mean 6 SEM of at least 10 animals per
group. C: Insulin sensitivity was determined after an intraperitoneal injection of insulin (0.75 units/kg body weight). Results are calculated as the
percentage of initial blood glucose levels. Data represent the mean6 SEM of at least eight animals per group. D: Glucose tolerance was determined
in fasted mice after an intraperitoneal injection of glucose (2 g/kg body weight), and blood glucose levels were measured at the indicated time
points. Data represent the mean 6 SEM of at least eight animals per group. E: Representative Western blots are shown for total Akt and phos-
phorylated Akt (p-Akt) levels in WAT and skeletal muscle (Sk.M) before and after insulin stimulation in chow- and HFD-fed mice, as indicated in
RESEARCH DESIGN AND METHODS. *P < 0.05 vs. Wt HFD. **P < 0.01 vs. Wt HFD. $$P < 0.01 vs. Wt chow.
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change of the anti-inﬂammatory milieu maintained by M2
macrophages toward an inﬂammatory state. Therefore, the
decrease in M1 proinﬂammatory and increased presence
of M2 anti-inﬂammatory macrophages in adipose tissue of
our mice may be protecting them from insulin resistance.
In line with our studies, the ablation of CD11c+ cells in mice
leads to a marked reduction in proinﬂammatory cytokines
and an improvement of insulin sensitivity (42). Further-
more, selective inactivation of peroxisome proliferator–
activated receptor (PPAR)-g in macrophages results in an
impairment of M2 macrophages maturation, leading to
insulin resistance and glucose intolerance (43). The amount
of dendritic cells and macrophages positive for MHCII was
also reduced. MHCII is often linked with increased in-
ﬂammatory response. Indeed, MHCII knockout mice exhibit
reduced secretion of proinﬂammatory cytokines in macro-
phages (44). In accordance with the reduced inﬁltration by
M1 macrophages, the expression of adipose tissue pro-
inﬂammatory cytokines, such as leptin, IFN-g, MCP-1, IL-6,
and TNF-a, was reduced in HFD-fed transgenic mice com-
pared with wild-type mice. This decrease may, in turn,
have led to lower grade of adipose tissue M1 macrophage
inﬁltration. Therefore, the reduction of M1 adipose tissue
macrophages and the lower proinﬂammatory cytokine se-
cretion in our mice may protect them from the development
of insulin resistance.
We demonstrate that VEGF enhances the presence of
M2 anti-inﬂammatory macrophages in the adipose tissue of
these mice. However, whether VEGF acts as a speciﬁc
chemotactic for M2 macrophages in adipose tissue or
promotes macrophage polarization switch toward an M2
phenotype remains unclear. The inability of VEGF to in-
crease the expression of M2 markers in BMDMs suggests
that VEGF alone is not able to induce the switch toward
the M2 phenotype. Recent studies have demonstrated that
another cytokine, adiponectin, is able to promote macro-
phage polarization toward an M2 phenotype (45,46).
However, adiponectin levels remained unchanged in our
model, thus excluding a role of this adipokine in the
transgenic phenotype. This suggests that VEGF is probably
attracting M2 macrophages to adipose tissue. Consistent
with this, VEGF plays a major role in wound repair and
angiogenesis, processes likely involving mobilization of
M2 macrophages (47,48). In addition, VEGF enhances
FIG. 7. Study of WAT and BAT inﬁltrates. A: MAC-2 immunohistochemistry was performed in WAT and BAT of wild-type (Wt) and transgenic (Tg)
mice (representative images at original magniﬁcation 3200). Red arrows indicate MAC-2 signal. Flow cytometry analysis of CD11b+ F480+ (B),
MHCII+ CD11b+ (C), MHCII+ CD11c+ (D), CD11chigh F4/80+ (E), and MGL1+ CD11b+ (F) cells in WAT. The stroma vascular fraction from Wt and
Tg mice fed chow or an HFD was double incubated with corresponding antibodies to detect different cell populations. Data represent the mean 6
SEM of at least ﬁve animals for each group. *P < 0.05 vs. Wt HFD. **P < 0.01 vs. Wt HFD. $P < 0.05 vs. Wt chow. $$P < 0.01 vs. Wt chow. (A high-
quality digital representation of this ﬁgure is available in the online issue.)
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angiogenesis in adipose tissue by inducing macrophage re-
cruitment and retention through its receptor VEGFR2 (Kdr)
(26). The chemokine SDF-1 (Cxcl12) is critical in this pro-
cess (26). Moreover, SDF-1 is upregulated by VEGF (49). In
agreement with this, expression of macrophage Kdr and
adipose tissue Cxcl12 were both increased in aP2VEGF
mice, suggesting that the increase in M2 macrophages is
due to the chemotactic activity of VEGF. Altogether, these
results suggest that VEGF may attract M2 macrophages to
adipose tissue through VEGFR2 and SDF1.
FIG. 8. Effects of VEGF on macrophage phenotype in transgenic (Tg) and wild-type (Wt) mice. A: Serum leptin levels were determined by enzyme-
linked immunosorbent assay (ELISA) as indicated in RESEARCH DESIGN AND METHODS. B: Lep expression in WAT was analyzed by quantitative real-time
PCR and normalized by 36B4 expression. C: Serum MCP-1 levels were determined by ELISA as indicated in RESEARCH DESIGN AND METHODS. D: Protein
MCP-1 levels in WAT were analyzed by Luminex and calculated as MCP-1 per total protein. WAT IFN-g (E), IL-6 (F), and TNF-a (G) levels were
determined by Luminex, as indicated in RESEARCH DESIGN AND METHODS, and results were calculated per total protein. H: Serum adiponectin levels were
determined by radioimmunoassay, as indicated in RESEARCH DESIGN AND METHODS. I: Adipoq expression in WAT was analyzed by quantitative real-time
PCR and normalized by 36B4 expression. BMDMs of Wt mice were treated with or without VEGF and Arg1 (J), Il10 (K), and Kdr (L) expression
levels were determined by quantitative real-time PCR and normalized by 36B4 expression. M: WAT Cxcl12 expression was analyzed by quantitative
real-time PCR and normalized by 36B4 expression. Data represent the mean6 SEM of at least 10 animals per group. *P< 0.05 vs. Wt HFD. **P< 0.01
vs. Wt HFD. $P < 0.05 vs. Wt chow. $$P < 0.01 vs. Wt chow.
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In summary, we show that overexpression of VEGF dis-
plays beneﬁcial effects. In BAT, our results highlight the
crucial role of vascularization in promoting its size and
thermogenesis as a means to counteract the development of
HFD-induced obesity. In WAT, the increase of angiogene-
sis promoted by VEGF overexpression did not lead to an
increase in adipose tissue mass. Moreover, adipose tissue
from animals overexpressing VEGF presented increased
recruitment of M2 anti-inﬂammatory macrophages, thus
maintaining an anti-inﬂammatory milieu and avoiding in-
sulin resistance. Therefore, targeting VEGF expression in
adipose tissue may offer the opportunity for a novel thera-
peutic approach to prevent or even treat the progression of
obesity-related insulin resistance.
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